In the January–March 2015 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory K. Bell and other industry experts discuss managing product liability in the pharma and healthcare sector. To read the article, click the link below.
ASCO 2024 review: The benefits and barriers of biomarkers in oncology
Biomarkers: what do we mean? – The term “biomarkers” can be broadly clustered into four categories: molecular, histologic, radiographic and physiological. –...